Literature DB >> 15731043

Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling.

Andreas Sturm1, Klaus Rilling, Daniel C Baumgart, Konstantinos Gargas, Tay Abou-Ghazalé, Bärbel Raupach, Jana Eckert, Ralf R Schumann, Corinne Enders, Ulrich Sonnenborn, Bertram Wiedenmann, Axel U Dignass.   

Abstract

Although the probiotic Escherichia coli strain Nissle 1917 has been proven to be efficacious for the treatment of inflammatory bowel diseases, the underlying mechanisms of action still remain elusive. The aim of the present study was to analyze the effects of E. coli Nissle 1917 on cell cycling and apoptosis of peripheral blood and lamina propria T cells (PBT and LPT, respectively). Anti-CD3-stimulated PBT and LPT were treated with E. coli Nissle 1917-conditioned medium (E. coli Nissle 1917-CM) or heat-inactivated E. coli Nissle 1917. Cyclin B1, DNA content, and caspase 3 expression were measured by flow cytometry to assess cell cycle kinetics and apoptosis. Protein levels of several cell cycle and apoptosis modulators were determined by immunoblotting, and cytokine profiles were determined by cytometric bead array. E. coli Nissle 1917-CM inhibits cell cycling and expansion of peripheral blood but not mucosal T cells. Bacterial lipoproteins mimicked the effect of E. coli Nissle 1917-CM; in contrast, heat-inactivated E. coli Nissle 1917, lipopolysaccharide, or CpG DNA did not alter PBT cell cycling. E. coli Nissle 1917-CM decreased cyclin D2, B1, and retinoblastoma protein expression, contributing to the reduction of T-cell proliferation. E. coli Nissle 1917 significantly inhibited the expression of interleukin-2 (IL-2), tumor necrosis factor alpha, and gamma interferon but increased IL-10 production in PBT. Using Toll-like receptor 2 (TLR-2) knockout mice, we further demonstrate that the inhibition of PBT proliferation by E. coli Nissle 1917-CM is TLR-2 dependent. The differential reaction of circulating and tissue-bound T cells towards E. coli Nissle 1917 may explain the beneficial effect of E. coli Nissle 1917 in intestinal inflammation. E. coli Nissle 1917 may downregulate the expansion of newly recruited T cells into the mucosa and limit intestinal inflammation, while already activated tissue-bound T cells may eliminate deleterious antigens in order to maintain immunological homeostasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731043      PMCID: PMC1064918          DOI: 10.1128/IAI.73.3.1452-1465.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  77 in total

1.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components.

Authors:  O Takeuchi; K Hoshino; T Kawai; H Sanjo; H Takada; T Ogawa; K Takeda; S Akira
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

2.  Immunology. Therapeutic manipulation of gut flora.

Authors:  F Shanahan
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

Review 3.  The structural and mechanical complexity of cell-growth control.

Authors:  S Huang; D E Ingber
Journal:  Nat Cell Biol       Date:  1999-09       Impact factor: 28.824

Review 4.  Cell death in development.

Authors:  D L Vaux; S J Korsmeyer
Journal:  Cell       Date:  1999-01-22       Impact factor: 41.582

Review 5.  Review article: Local and systemic regulation of mucosal immunity.

Authors:  L Mayer
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

6.  Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD 098059.

Authors:  S Mohr; T S McCormick; E G Lapetina
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

7.  The effect of orally administered viable probiotic and dairy lactobacilli on mouse lymphocyte proliferation.

Authors:  P V Kirjavainen; H S El-Nezami; S J Salminen; J T Ahokas; P F Wright
Journal:  FEMS Immunol Med Microbiol       Date:  1999-11

Review 8.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.

Authors:  M Lenardo; K M Chan; F Hornung; H McFarland; R Siegel; J Wang; L Zheng
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

Review 9.  Novel therapies for inflammatory bowel disease.

Authors:  B E Sands
Journal:  Gastroenterol Clin North Am       Date:  1999-06       Impact factor: 3.806

10.  Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease.

Authors:  A Darfeuille-Michaud; C Neut; N Barnich; E Lederman; P Di Martino; P Desreumaux; L Gambiez; B Joly; A Cortot; J F Colombel
Journal:  Gastroenterology       Date:  1998-12       Impact factor: 22.682

View more
  57 in total

Review 1.  Intestinal effect of the probiotic Escherichia coli strain Nissle 1917 and its OMV.

Authors:  Ava Behrouzi; Hoora Mazaheri; Sarvenaz Falsafi; Zahra Hoseini Tavassol; Arfa Moshiri; Seyed Davar Siadat
Journal:  J Diabetes Metab Disord       Date:  2020-05-01

2.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

Review 3.  Probiotics manipulate host cytokine response and induce antimicrobial peptides.

Authors:  I Trebichavský; I Splíchal
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

Review 4.  Probiotics and inflammatory bowel diseases.

Authors:  A-P Bai; Q Ouyang
Journal:  Postgrad Med J       Date:  2006-06       Impact factor: 2.401

Review 5.  Probiotics and prebiotics in chronic inflammatory bowel diseases.

Authors:  Julia B Ewaschuk; Levinus A Dieleman
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

6.  Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.

Authors:  A Grabig; D Paclik; C Guzy; A Dankof; D C Baumgart; J Erckenbrecht; B Raupach; U Sonnenborn; J Eckert; R R Schumann; B Wiedenmann; A U Dignass; A Sturm
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 7.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

8.  Enteral and parenteral nutrition distinctively modulate intestinal permeability and T cell function in vitro.

Authors:  Claudia Guzy; Anja Schirbel; Daniela Paclik; Bertram Wiedenmann; Axel Dignass; Andreas Sturm
Journal:  Eur J Nutr       Date:  2008-11-08       Impact factor: 5.614

Review 9.  Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.

Authors:  Franco Scaldaferri; Viviana Gerardi; Francesca Mangiola; Loris Riccardo Lopetuso; Marco Pizzoferrato; Valentina Petito; Alfredo Papa; Jovana Stojanovic; Andrea Poscia; Giovanni Cammarota; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

10.  Probiotics and small bowel mucosa: Molecular aspects of their interactions.

Authors:  N Saulnier; M A Zocco; S Di Caro; G Gasbarrini; A Gasbarrini
Journal:  Genes Nutr       Date:  2006-06       Impact factor: 5.523

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.